- Home
- CDNA vs MDXG Comparison
CDNA vs MDXG Comparison
Compare CDNA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- MDXG
- Stock Information
- Founded
- CDNA 1998
- MDXG 2006
- Country
- CDNA United States
- MDXG United States
- Employees
- CDNA N/A
- MDXG N/A
- Industry
- CDNA Medical Specialities
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- MDXG Health Care
- Exchange
- CDNA Nasdaq
- MDXG Nasdaq
- Market Cap
- CDNA 1.1B
- MDXG 1.1B
- IPO Year
- CDNA 2014
- MDXG N/A
- Fundamental
- Price
- CDNA $21.44
- MDXG $9.12
- Analyst Decision
- CDNA Buy
- MDXG Strong Buy
- Analyst Count
- CDNA 8
- MDXG 5
- Target Price
- CDNA $26.43
- MDXG $12.00
- AVG Volume (30 Days)
- CDNA 851.0K
- MDXG 674.7K
- Earning Date
- CDNA 02-26-2025
- MDXG 02-26-2025
- Dividend Yield
- CDNA N/A
- MDXG N/A
- EPS Growth
- CDNA N/A
- MDXG N/A
- EPS
- CDNA N/A
- MDXG 0.52
- Revenue
- CDNA $312,775,000.00
- MDXG $342,804,000.00
- Revenue This Year
- CDNA $19.85
- MDXG $9.56
- Revenue Next Year
- CDNA $11.34
- MDXG $9.19
- P/E Ratio
- CDNA N/A
- MDXG $18.12
- Revenue Growth
- CDNA 5.26
- MDXG 10.93
- 52 Week Low
- CDNA $7.42
- MDXG $5.47
- 52 Week High
- CDNA $34.84
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- CDNA 43.79
- MDXG 53.35
- Support Level
- CDNA $21.09
- MDXG $8.50
- Resistance Level
- CDNA $25.95
- MDXG $9.71
- Average True Range (ATR)
- CDNA 1.61
- MDXG 0.30
- MACD
- CDNA 0.02
- MDXG -0.04
- Stochastic Oscillator
- CDNA 19.46
- MDXG 51.24
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.